New Orleans, LA - In a somewhat idiosyncratic presentation at the American Heart Association Scientific Sessions 2004, Dr Victor Serebruany (HeartDrug Research, Towson, MD) claimed that reports of ...
December 7, 2009 (Towson, Maryland) — In a new paper that turns the notion of clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) nonresponsiveness on its head, researchers propose that a high ...
DALLAS, June 8 – A substantial proportion of heart attack patients may be resistant to the blood thinner clopidogrel – and face an increased risk of recurrent blockages, researchers report in today's ...
Switching from clopidogrel to ticagrelor without use of a loading dose does not adversely affect platelet inhibition in patients with acute coronary syndromes (ACS), reports a pharmacodynamic study ...
SAN FRANCISCO, CA – According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention (PCI) may help cardiology teams adjust treatment and improve ischemic outcomes ...
Dual antiplatelet therapy with a thienopyridine in combination with aspirin for 1 to 6 months after stenting has been recommended by the manufacturers to reduce ischemic cardiovascular events and ...
Clopidogrel is a generic prescription medication. It is FDA-approved to help prevent cardiovascular events such as heart attack and stroke in certain adults. Specifically, clopidogrel is approved to ...
Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA). A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results